Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease

Circulation

Volumn 134, Issue 8, 2016, Pages 589-598

  Ezekowitz, Michael D ^a,b   Nagarakanti, Rangadham ^c,d   Noack, Herbert ^e   Brueckmann, Martina ^e,f   Litherland, Claire ^b   Jacobs, Mark ^g   Clemens, Andreas ^h   Reilly, Paul A ⁱ   Connolly, Stuart J ^j   Yusuf, Salim ^j   Wallentin, Lars ^k  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d Electrophysiology Research Foundation   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

ⁱ BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^j MCMASTER UNIVERSITY   (Canada)

^k UPPSALA CLINICAL RESEARCH CENTER   (Sweden)

more..

Author keywords

atrial fibrillation; stroke; valvular heart diseases

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; AORTA STENOSIS; AORTA VALVE REGURGITATION; ARTICLE; ATRIAL FIBRILLATION; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; EMBOLISM; FEMALE; HEART FAILURE; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; MITRAL VALVE STENOSIS; MORTALITY RATE; PERSISTENT ATRIAL FIBRILLATION; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRICUSPID VALVE REGURGITATION; VALVULAR HEART DISEASE; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG ADMINISTRATION; HEART VALVE DISEASES; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TIME FACTOR;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COHORT STUDIES; DABIGATRAN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART VALVE DISEASES; HUMANS; MALE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TIME FACTORS; WARFARIN;

EID: 84981727734     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.020950     Document Type: Article

References (14)

1. Ezekowitz MD, Connolly S, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J. 2009; 157: 805-10, 810.e1. doi: 10.1016/j.ahj.2009.02.005
2. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361: 1139-1151. doi: 10.1056/NEJMoa0905561
3. Executive Steering Committee on behalf of the ROCKET AF Study Investigators. Rivaroxaban-Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J. 2010; 159: 340-347
4. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365: 883-891. doi: 10.1056/NEJMoa1009638
5. Lopes RD, Alexander JH, Al-Khatib SM, Ansell J, Diaz R, Easton JD, Gersh BJ, Granger CB, Hanna M, Horowitz J, Hylek EM, McMurray JJ, Verheugt FW, Wallentin L; ARISTOTLE Investigators. Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale. Am Heart J. 2010; 159: 331-339. doi: 10.1016/j.ahj.2009.07.035
6. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011; 365: 981-992. doi: 10.1056/NEJMoa1107039
7. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013; 369: 2093-2104. doi: 10.1056/NEJMoa1310907
8. Ruff CT, Giugliano RP, Antman EM, Crugnale SE, Bocanegra T, Mercuri M, Hanyok J, Patel I, Shi M, Salazar D, McCabe CH, Braunwald E. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor XA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010; 160: 635-641. doi: 10.1016/j.ahj.2010.06.042
9. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, Lokhnygina Y, Patel MR, Halperin JL, Singer DE, Hankey GJ, Hacke W, Becker RC, Nessel CC, Mahaffey KW, Fox KA, Califf RM; ROCKET AF Steering Committee, & Investigators. Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial. Eur Heart J. 2014; 35: 3377-3385. doi: 10.1093/eurheartj/ehu305
10. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, Pais P, Erol C, Diaz R, Bahit MC, Bartunek J, De Caterina R, Goto S, Ruzyllo W, Zhu J, Granger CB, Alexander JH. Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation. 2015; 132: 624-632. doi: 10.1161/CIRCULATIONAHA. 114.014807
11. Heidbuchel H, Verhamme P, Alings M, Antz M, Diener HC, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. Updated European Heart Rhythm Association practical guide on the use of nonvitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015; 17: 1467-1507. doi: 10.1093/europace/euv309
12. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014; 130: e199-e267. doi: 10.1161/CIR.0000000000000041
13. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2015. https://www.R-project.org/
14. Wickham H. ggplot2: Elegant Graphics for Data Analysis. New York, NY: Springer; 2009